Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on <i>nab</i>-paclitaxel plus gemcitabine versus FOLFIRINOX

McBride, Ali; Bonafede, Machaon; Cai, Qing; Princic, Nicole; Tran, Oth; Pelletier, Corey; Parisi, Monika

doi:10.1080/17512433.2017.1365598

Cited by 42 publications

(30 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even for patients with localized and resectable tumours, the 5-year OS rate is only approximately 27% [7]. Chemotherapy based on gemcitabine (Gem) is currently the standard treatment for metastatic PDAC, and the combination of Gem with oxaliplatin, irinotecan, leucovorin and 5-fluorouracil (FOLFIRINOX) can reduce the mortality rate but has been shown to increase toxicity and to have a poor survival benefit and high cost burden [8,9]. Therefore, the exploration of new therapies for PDAC is urgently needed.…”

Section: Introductionmentioning

confidence: 99%

Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma

et al. 2020

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is an incurable cancer resistant to traditional treatments, although a limited number of early-stage patients can undergo radical resection. Immunotherapies for the treatment of haematological malignancies as well as solid tumours have been substantially improved over the past decades, and impressive results have been obtained in recent preclinical and clinical trials. However, PDAC is likely the exception because of its unique tumour microenvironment (TME). In this review, we summarize the characteristics of the PDAC TME and focus on the network of various tumour-infiltrating immune cells, outlining the current advances in PDAC immunotherapy and addressing the effect of the PDAC TME on immunotherapy. This review further explores the combinations of different therapies used to enhance antitumour efficacy or reverse immunodeficiencies and describes optimizable immunotherapeutic strategies for PDAC. The concordant combination of various treatments, such as targeting cancer cells and the stroma, reversing suppressive immune reactions and enhancing antitumour reactivity, may be the most promising approach for the treatment of PDAC. Traditional treatments, especially chemotherapy, may also be optimized for individual patients to remodel the immunosuppressive microenvironment for enhanced therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…And the basic health conditions of patients should be evaluated as GEM-NAB was less toxic compared to triplet therapy. Furthermore, patients should be noti ed with the costs of supportive care such as apply of anti-emetics or peg lgrastim [54]. Costs are not only based on chemotherapy drug itself but also on supportive treatment determined by severity and frequency of adverse effects.…”

Section: Discussionmentioning

confidence: 99%

Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer

Chen

Hua

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Modified FOLFIRINOX and gemcitabine plus nab-paclitaxel (GEM-NAB) have been recommended as first-line therapies for advanced pancreatic cancer (PC) at present. Due to the lack of direct comparison, we conducted this network meta-analysis to indirectly compare the effectiveness and toxicity of modified FOLFIRINOX and GEM-NAB. Methods: The eligible retrospective studies of treatments related to modified FOLFIRINOX and GEM-NAB were searched up to 4 April 2020. We used the frequentist model to analyze the survival and toxicity data between different treatments. Pooled analysis for overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and events of toxicity were analyzed in this study.Results: Twenty-two studies including 6351 patients were involved in this network meta-analysis. The comparisons based on OS and PFS showed that modified FOLFIRINOX and GEM-NAB had similar treatment efficacy. But GEM-NAB was more effective than modified FOLFIRINOX based on the result of ORR (RR: 0.70; 95% CI: 0.51-0.96). Moreover, our analysis showed a similar toxicity profile between modified FOLFIRINOX and GEM-NAB. Conclusions: Based on current evidence, modified FOLFIRINOX and GEM-NAB were similar in survival and toxicity comparisons. Many factors should be considered for the optimal treatment formulation and our meta-analysis could provide some guidance to treatment selection in the first-line setting for advanced PC.

show abstract

“… 18 These data indicate that nab-paclitaxel plus Gem has a manageable safety profile and is an effective first-line option in patients in Western Europe with MPC. 21 – 23 …”

Section: Discussionmentioning

confidence: 99%

Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer

Luca¹,

Blasi²,

Alù³

et al. 2018

DDDT

View full text Add to dashboard Cite

PurposePancreatic carcinoma is the neoplasia with the major mortality, and main standard treatments in this cancer increase survival but do not lead to complete recovery of the patient. The aim of this study was to evaluate the efficacy of Abraxane® (nab-paclitaxel) in Italian patients with metastatic pancreatic cancer (MPC).Patients and methodsWe conducted a retrospective analysis of 80 patients. Overall survival (OS) was the primary end point for evaluating the efficacy of nab-paclitaxel in combination with gemcitabine treatment, while carbohydrate antigen 19-9 (CA 19-9) reduction, safety, progression-free survival (PFS), overall response rate and reduction in pain were secondary end points.ResultsThe median OS was 8 months, and the median PFS was 5 months. A considerable difference in CA 19-9 before and after treatment was observed. Descriptive and correlation analyses were done to examine the relationship between CA 19-9 response and OS. Linear regression analysis between OS and CA 19-9 response revealed that CA 19-9 is an important predictor of OS, showing a positive correlation.ConclusionNab-paclitaxel is a well-tolerated and effective treatment for patients affected by MPC. The drug showed an improved tolerability profile, significant pain relief and an increase in survival rate.

show abstract

Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on nab-paclitaxel plus gemcitabine versus FOLFIRINOX

Cited by 42 publications

References 13 publications

Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma

Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma

Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer

Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer

Contact Info

Product

Resources

About